COMP <GO>
PDEX vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Pro-Dex Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: PDEX 5
— ABBV 8
■ METRIC PARITY
LAST: $61.60 (-2.52%) • MKT CAP: $199.2M
options-implied-move
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PDEX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PDEX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 29.30% | 70.20% | -40.90 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 23.20% | 29.00% | -5.80 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.5x | 33.3x | -16.80 | PDEX | /valuation <GO> |
| Free Cash Flow Yield | -1.47% | 3.47% | -4.94 | ABBV | /fcf-yield <GO> |
| Operating Margin | 16.10% | 24.60% | -8.50 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 13.50% | 6.90% | +6.60 | PDEX | /net-margins <GO> |
| Revenue Growth (YoY) | 23.70% | 8.60% | +15.10 | PDEX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.08 | 5.33 | +3.75 | PDEX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.7 | 65.1 | -17.40 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.6x | 113.1x | -94.50 | PDEX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $199.2M | $513.86B | -$513.66B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PDEX REV | ABBV REV | PDEX GROSS % | ABBV GROSS % | PDEX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $66.6M | $61.16B | 29.3% | 70.2% | -$2.9M | $17.82B |
| FY 2024 | $53.8M | $56.33B | 27.0% | 70.0% | $6.2M | $17.83B |
| FY 2023 | $46.1M | $54.32B | — | — | $5.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PDEX // BETA —
ABBV // BETA 1.15